These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20190473)

  • 1. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C.
    Yamazaki M; Sato A; Takeda T; Komatsu M
    Intern Med; 2010; 49(5):403-7. PubMed ID: 20190473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.
    Tanaka J; Sugimoto K; Shiraki K; Beppu T; Yoneda K; Fuke H; Yamamoto N; Ito K; Takei Y
    Intern Med; 2008; 47(8):747-9. PubMed ID: 18421192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis.
    Popescu C; Popescu GA; Arama V
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):101-4. PubMed ID: 23539399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha.
    Eibl N; Gschwantler M; Ferenci P; Eibl MM; Weiss W; Schernthaner G
    Eur J Gastroenterol Hepatol; 2001 Mar; 13(3):295-8. PubMed ID: 11293453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Hayashi M; Kataoka Y; Tachikawa K; Koguchi H; Tanaka H
    Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
    Vinagre I; Rigla M; Torras X; Enríquez J; Corcoy R
    Endocrinol Nutr; 2010 Oct; 57(8):393-5. PubMed ID: 20462813
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C].
    Primo Vera J
    Gastroenterol Hepatol; 2004 Feb; 27(2):69. PubMed ID: 14733882
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy.
    Uto H; Matsuoka H; Murata M; Okamoto T; Miyata Y; Hori T; Ido A; Hirono S; Hayashi K; Tsubouchi H
    Diabetes Res Clin Pract; 2000 Aug; 49(2-3):101-6. PubMed ID: 10963820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C.
    Fujioka T; Honda M; Yoshizaki T; Ogawa M; Matsuno H; Shimokawa K; Koyama K
    Intern Med; 2010; 49(18):1987-90. PubMed ID: 20847504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus.
    Yagyu H; Okada K; Sato S; Yamashita Y; Okada N; Osuga J; Nagasaka S; Sugano K; Ishibashi S
    Diabetes Res Clin Pract; 2012 Mar; 95(3):e52-4. PubMed ID: 22154462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.
    Cozzolongo R; Betterle C; Fabris P; Paola Albergoni M; Lanzilotta E; Manghisi OG
    Eur J Gastroenterol Hepatol; 2006 Jun; 18(6):689-92. PubMed ID: 16702861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trajectories of anti-islet autoantibodies before development of type 1 diabetes in interferon-treated hepatitis C patients. Case reports and a literature review.
    Nakamura K; Kawasaki E; Abiru N; Jo O; Fukushima K; Satoh T; Kuriya G; Kobayashi M; Kuwahara H; Yamasaki H; Ide T; Eguchi K
    Endocr J; 2010; 57(11):947-51. PubMed ID: 20805634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C].
    Lee YN; Jeong SW; Lim JH; Ryu YS; Jeon SR; Kim SK; Jang JY; Kim YS; Kim BS; Roh MO
    Korean J Hepatol; 2010 Jun; 16(2):187-91. PubMed ID: 20606504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.
    Soultati AS; Dourakis SP; Alexopoulou A; Deutsch M; Archimandritis AJ
    World J Gastroenterol; 2007 Feb; 13(8):1292-4. PubMed ID: 17451219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 17. Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C.
    Ogihara T; Katagiri H; Yamada T; Kudo H; Imai J; Ishigaki Y; Hinokio Y; Yamagiwa Y; Ueno Y; Shimosegawa T; Oka Y
    Intern Med; 2009; 48(16):1387-90. PubMed ID: 19687584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-α induced lupus in a patient with chronic hepatitis C virus.
    Rizvi R; Hojjati M
    J Clin Rheumatol; 2011 Apr; 17(3):152-3. PubMed ID: 21441813
    [No Abstract]   [Full Text] [Related]  

  • 19. [Consensus and peg-interferon in chronic hepatitis C. Therapy for refractory cases?].
    Kaiser S
    MMW Fortschr Med; 2001 Apr; 143(16):36-7. PubMed ID: 11367991
    [No Abstract]   [Full Text] [Related]  

  • 20. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis.
    Shiba T; Morino Y; Tagawa K; Fujino H; Unuma T
    Diabetes Res Clin Pract; 1995 Dec; 30(3):237-41. PubMed ID: 8861464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.